Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
112.5 USD | +0.29% | +1.98% | -9.35% |
Jun. 26 | Wall Street: up, on the edge, despite rates | CF |
Jun. 25 | Out with AI, in with defensive stocks |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 67% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.1 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.35% | 44.61B | B- | ||
-6.24% | 180B | C+ | ||
-6.08% | 98.89B | C | ||
-5.98% | 66.26B | A | ||
+8.34% | 44.02B | B- | ||
+10.24% | 40.12B | B+ | ||
+11.88% | 29.19B | B | ||
-8.38% | 23.64B | A- | ||
+14.95% | 23.41B | A- | ||
-12.68% | 21.8B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DXCM Stock
- Ratings DexCom, Inc.